Press releases

2013

Cardio3 BioSciences Treats First Patients in World’s First Phase III Clinical Trial Using Pre-Programmed Cells for the Treatment of Heart Failure
> Read the press release : En - Fr - Nl

Cardio3 BioSciences raises €19 million through a Private Placement
> Read the press release : En - Fr - Nl

Results from Cardio3BioSciences C-Cure® Trial published in the Journal of the American College of Cardiology
> Read the press release : En - Fr - Nl

2012

Cardio3 BioSciences Receives Authorization to Begin World's First Phase III Clinical Trial in Regenerative Medicine for Heart Failure
> Read the press release : En - Fr - Nl

Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at European Society of Cardiology 2012 Heart Failure Congress
> Read the press release : En

Cardio3 BioSciences Announces CE Marking for its C-Cath® Injection Catheter
> Read the press release : En - Fr - Nl

Cardio3 BioSciences Granted GMP Certification
> Read the press release : En - Fr - Nl

Cardio3 BioSciences Receives ISO-13485 Certification
> Read the press release : En

Cardio3 BioSciences Secures Additional €3.1 million in Non-dilutive Funding from the Walloon Region and the European Commission
> Read the press release : En - Fr - Nl

2011

Cardio3 BioSciences Establishes US Subsidiary in Rochester, MN
> Read the press release : En

Belgian economic mission in the U.S. is a success for Cardio3 BioSciences Cardio3 BioSciences and ATMI, Inc.Sign a Letter of intent
> Read the press release : En - Fr - Nl

Cardio3 BioSciences Presents C-Cure® Phase II Clinical Trial Results at the EuroPCR Meeting
> Read the press release : En

Cardio3 BioSciences Announces International C-Cure® Phase II Clinical Trial at the 60th Annual American College of Cardiology Meeting
> Read the press release : En - Fr - Nl

Cardio3 BioSciences Announces its new Board Members
> Read the press release : En - Fr - Nl